Esperion Therapeutics, Inc. is a biopharmaceutical company focused on the research, development and commercialization of therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol (LDL-C) and other cardiometabolic risk factors.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/25/13 | $33,000,000 |
Aisling Capital Alta Partners Arboretum Ventures Asset Management Ventures Domain Associates Longitude Capital | undisclosed |
